How to buy Pfizer stock in Canada

Pfizer is a drug manufacturers - general business based in the US. Pfizer shares (PFE) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $22.28 , which is a decrease of 7.93% over the previous week. Pfizer employs 81,000 staff and has a trailing 12-month revenue of around $62.5 billion.

Our top picks for where to buy Pfizer stock

Buy Pfizer stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Pfizer stock price (NYSE: PFE)

Use our graph to track the performance of PFE stocks over time.

Pfizer stocks at a glance

• Key figures

Information last updated 2025-05-05.

Latest market close	$22.28
52-week range	$20.53 - $29.98
50-day moving average more info button	$24.71
200-day moving average more info button	$27.02
Wall St. target price	$29.20
PE ratio more info button	16.8723
Dividend yield more info button	$1.69 (7.23%)
Earnings per share (TTM) more info button	$1.41

Is it a good time to buy Pfizer stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is Pfizer stock undervalued or overvalued?

Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pfizer's P/E ratio

Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Pfizer shares trade at around 17x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stock or simply that they're under-valued.

Pfizer's PEG ratio

Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6097. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Pfizer's EBITDA

Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $23.5 billion.

The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.

Pfizer financials

Revenue TTM	$62.5 billion
Operating margin TTM	36.46%
Gross profit TTM	$46.5 billion
Return on assets TTM	4.64%
Return on equity TTM	9.06%
Profit margin	12.62%
Book value	$15.56
Market Capitalization more info button	$134.9 billion

TTM: trailing 12 months

Pfizer stock dividends

Dividend payout ratio: 41.94% of net profits

Recently Pfizer has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.69 per share.

While Pfizer's payout ratio might seem fairly standard, it's worth remembering that Pfizer may be investing much of the rest of its net profits in future growth.

Pfizer's most recent dividend payout was on 12 June 2025. The latest dividend was paid out to all shareholders who bought their stocks by 8 May 2025 (the "ex-dividend date").

Have Pfizer's stocks ever split?

Pfizer's stocks were split on a 1054:1000 basis on 16 November 2020 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer stocks – just the quantity. However, indirectly, the new 5.1% lower stock price could have impacted the market appetite for Pfizer stocks, which in turn could have impacted Pfizer's stock price.

Pfizer stock price volatility

Over the last 12 months, Pfizer's stocks have ranged in value from as little as $20.5284 up to $29.9806. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.597. This would suggest that Pfizer's stocks are less volatile than average (for this exchange).

Pfizer overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Pfizer is owned by insiders or institutions?
Currently 0.056% of Pfizer stocks are held by insiders and 67.791% by institutions. How many people work for Pfizer?
Latest data suggests 81,000 work at Pfizer. When does the fiscal year end for Pfizer?
Pfizer's fiscal year ends in December. Where is Pfizer based?
Pfizer's address is: 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 What is Pfizer's ISIN number?
Pfizer's international securities identification number is: US7170811035 What is Pfizer's CUSIP number?
Pfizer's Committee on Uniform Securities Identification Procedures number is: 717081103

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.